Skip to main content
Locate a specialist
Patient and carer information
Health professional information

ASCIA News

  • Update on Alfamino® Infant Formula PBS listings - 1 August 2024
    Nestlé Health Science has informed ASCIA that only the updated recipe of Alfamino® amino acid formula for infants will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 August 2024. Since 1 September 2023, both the newer and older recipe Alfamino® products...
  • Alfaré® infant formula to be deleted from PBS - 1 August 2024
    Nestlé Health Science has informed ASCIA that supply of Alfaré® extensively hydrolysed infant formula (400g) is being discontinued in Australia and will be deleted from the Pharmaceutical Benefits Scheme (PBS) on 1 August 2024. There will be a supply only period, which...
  • Updated ASCIA Adrenaline Device PBS Authority Form
    ASCIA recommends the use of adrenaline (epinephrine) as the first line emergency/first aid treatment for severe allergic reactions (anaphylaxis) using either of the following two brands of adrenaline injector devices, EpiPen® or Anapen®, which are both available in...
  • ASCIA 2024 Conference registration is still open
    Registration is still open for the ASCIA 2024 Conference at https://ascia2024.com/registration To date there are 455 registered delegates (80% in person), a sold out exhibition and more than 150 abstracts have been received for posters and clinical grand rounds. Authors will...
  • Updates to Australian medicine labelling rules to support medicine safety
    The Therapeutic Goods Administration (TGA) public consultation is now open on Updates to Australian medicine labelling rules to support medicine safety to seek feedback to make sure proposed changes to labelling rules support the safe use of medicines. The TGA is proposing...
  • Allergic reactions to Andrographis paniculata
    The ASCIA website article on Adverse Reactions to Complementary and Alternative Medicine has been updated to include information about Andrographis paniculata. This herb is commonly used in Indian and Chinese medicine and is known as the 'king of bitters'. Since 2019, the...
  • Saphnelo (anifrolumab) listed on the PBS for patients with severe SLE - 1 July 2024
    Saphnelo® (anifrolumab) has been listed on the Pharmaceutical Benefits Scheme (PBS) for patients with severe Systemic Lupus Erythematosus (SLE) with high disease activity despite standard of care from Monday 1 July 2024. ​ The listing details have been published on the PBS...
  • Product Update - Anapen® Adrenaline Injector Devices
    Arrotex Pharmaceuticals has advised that the sale and distribution of Anapen® Junior 150 and Anapen® 300 used for the emergency treatment of anaphylaxis are to cease in Australia: Anapen® 300 will be available until end July 2024. Anapen® Junior 150 will be available until...
More ASCIA News
ASCIA Member Login
Site last updated: 11 Jun 2024
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...